Recent advances in clinical approaches, such as the combined inhibition of BRAFV600 and MEK and of immune checkpoint therapy for advanced-stage melanomas, have significantly reduced melanoma mortality (Bai and Flaherty 2021; Sacchetto et al. 2021). Here, MAP2K7 is linked to melanoma.